LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Princess Margaret Cancer Centre
Toronto, CanadáPublicaciones en colaboración con investigadores/as de Princess Margaret Cancer Centre (5)
2022
2017
-
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Lung Cancer, Vol. 112, pp. 181-187
-
Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)
Journal of Clinical Oncology
2016
2015
-
A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Clinical Cancer Research, Vol. 21, Núm. 4, pp. 730-738